Per 10 000 screened men, use of a Stockholm3 risk score of 0.15 or higher followed by systematic biopsies would reduce the number of MRI scans by 1100, but 191 additional biopsies would be required to find 65 additional low-grade prostate cancers while 20 clinically significant prostate cancers would be missed compared with the number missed with the use of PSA-level screening followed by MRI and biopsies (Figure 2). The gene discussed is KLK3; the disease is prostate carcinoma.